$3.59
2.71%
Nasdaq, Aug 29, 10:00 pm CET
ISIN
US75943R1023
Symbol
RLAY

Relay Therapeutics Inc Target price 2025 - Analyst rating & recommendation

Relay Therapeutics Inc Classifications & Recommendation:

Buy
83%
Hold
17%

Relay Therapeutics Inc Price Target

Target Price $13.77
Price $3.59
Potential
Number of Estimates 12
12 Analysts have issued a price target Relay Therapeutics Inc 2026 . The average Relay Therapeutics Inc target price is $13.77. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 18 analysts: 15 Analysts recommend Relay Therapeutics Inc to buy, 3 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Relay Therapeutics Inc stock has an average upside potential 2026 of . Most analysts recommend the Relay Therapeutics Inc stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 10.01 13.16
60.82% 31.51%
EBITDA Margin -3,666.33% -2,743.21%
154.74% 25.18%
Net Margin -3,373.73% -2,228.43%
152.07% 33.95%

13 Analysts have issued a sales forecast Relay Therapeutics Inc 2025 . The average Relay Therapeutics Inc sales estimate is

$13.2m
Unlock
. This is
57.46% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$40.3m 382.30%
Unlock
, the lowest is
$7.5m 9.74%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $10.0m 60.82%
2025
$13.2m 31.51%
Unlock
2026
$11.9m 9.68%
Unlock
2027
$26.6m 123.78%
Unlock
2028
$12.1m 54.54%
Unlock
2029
$105m 771.10%
Unlock
2030
$283m 168.84%
Unlock
2031
$505m 78.14%
Unlock
2032
$726m 43.87%
Unlock

5 Analysts have issued an Relay Therapeutics Inc EBITDA forecast 2025. The average Relay Therapeutics Inc EBITDA estimate is

$-361m
Unlock
. This is
6.79% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-326m 3.60%
Unlock
, the lowest is
$-368m 8.93%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $-367m 0.20%
2025
$-361m 1.60%
Unlock
2026
$-372m 3.04%
Unlock
2027
$-348m 6.40%
Unlock
2028
$-293m 15.83%
Unlock
2029
$-132m 54.95%
Unlock
2030
$75.4m 157.09%
Unlock
2031
$232m 207.83%
Unlock
2032
$367m 58.31%
Unlock

EBITDA Margin

2024 -3,666.33% 154.74%
2025
-2,743.21% 25.18%
Unlock
2026
-3,129.57% 14.08%
Unlock
2027
-1,309.09% 58.17%
Unlock
2028
-2,423.88% 85.16%
Unlock
2029
-125.35% 94.83%
Unlock
2030
26.62% 121.24%
Unlock
2031
46.00% 72.80%
Unlock
2032
50.61% 10.02%
Unlock

14 Relay Therapeutics Inc Analysts have issued a net profit forecast 2025. The average Relay Therapeutics Inc net profit estimate is

$-293m
Unlock
. This is
5.84% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-222m 28.83%
Unlock
, the lowest is
$-321m 3.15%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-338m 1.25%
2025
$-293m 13.14%
Unlock
2026
$-286m 2.60%
Unlock
2027
$-313m 9.51%
Unlock
2028
$-203m 35.26%
Unlock
2029
$-149m 26.23%
Unlock
2030
$-32.7m 78.12%
Unlock
2031
$119m 464.16%
Unlock
2032
$189m 58.83%
Unlock

Net Margin

2024 -3,373.73% 152.07%
2025
-2,228.43% 33.95%
Unlock
2026
-2,402.98% 7.83%
Unlock
2027
-1,175.96% 51.06%
Unlock
2028
-1,674.79% 42.42%
Unlock
2029
-141.83% 91.53%
Unlock
2030
-11.54% 91.86%
Unlock
2031
23.60% 304.51%
Unlock
2032
26.05% 10.38%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -2.36 -1.71
15.41% 27.54%
P/E negative
EV/Sales negative

14 Analysts have issued a Relay Therapeutics Inc forecast for earnings per share. The average Relay Therapeutics Inc EPS is

$-1.71
Unlock
. This is
5.52% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-1.29 28.73%
Unlock
, the lowest is
$-1.87 3.31%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-2.36 15.41%
2025
$-1.71 27.54%
Unlock
2026
$-1.66 2.92%
Unlock
2027
$-1.82 9.64%
Unlock
2028
$-1.18 35.16%
Unlock
2029
$-0.87 26.27%
Unlock
2030
$-0.19 78.16%
Unlock
2031
$0.69 463.16%
Unlock
2032
$1.10 59.42%
Unlock

P/E ratio

Current -1.98 20.38%
2025
-2.10 5.88%
Unlock
2026
-2.16 2.86%
Unlock
2027
-1.97 8.80%
Unlock
2028
-3.04 54.31%
Unlock
2029
-4.12 35.53%
Unlock
2030
-18.85 357.52%
Unlock
2031
5.18 127.48%
Unlock
2032
3.26 37.07%
Unlock

Based on analysts' sales estimates for 2025, the Relay Therapeutics Inc stock is valued at an EV/Sales of

-2.87
Unlock
and an P/S ratio of
47.02
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current -4.52 199.56%
2025
-2.87 36.44%
Unlock
2026
-3.18 10.71%
Unlock
2027
-1.42 55.31%
Unlock
2028
-3.13 119.99%
Unlock
2029
-0.36 88.52%
Unlock
2030
-0.13 62.81%
Unlock
2031
-0.08 43.82%
Unlock
2032
-0.05 30.53%
Unlock

P/S ratio

Current 74.04 366.57%
2025
47.02 36.49%
Unlock
2026
52.06 10.72%
Unlock
2027
23.26 55.31%
Unlock
2028
51.17 119.98%
Unlock
2029
5.87 88.52%
Unlock
2030
2.19 62.80%
Unlock
2031
1.23 43.86%
Unlock
2032
0.85 30.50%
Unlock

Current Relay Therapeutics Inc Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
HC Wainwright & Co.
Locked
Locked
Locked Aug 26 2025
Raymond James
Locked
Locked
Locked Aug 08 2025
Guggenheim
Locked
Locked
Locked May 07 2025
Wells Fargo
Locked
Locked
Locked Apr 17 2025
HC Wainwright & Co.
Locked
Locked
Locked Mar 07 2025
Stifel
Locked
Locked
Locked Feb 27 2025
Goldman Sachs
Locked
Locked
Locked Feb 27 2025
Analyst Rating Date
Locked
HC Wainwright & Co.:
Locked
Locked
Aug 26 2025
Locked
Raymond James:
Locked
Locked
Aug 08 2025
Locked
Guggenheim:
Locked
Locked
May 07 2025
Locked
Wells Fargo:
Locked
Locked
Apr 17 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Mar 07 2025
Locked
Stifel:
Locked
Locked
Feb 27 2025
Locked
Goldman Sachs:
Locked
Locked
Feb 27 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today